These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 28042310)
21. Vinflunine in the treatment of bladder cancer. Bachner M; De Santis M Ther Clin Risk Manag; 2008 Dec; 4(6):1243-53. PubMed ID: 19337431 [TBL] [Abstract][Full Text] [Related]
22. Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial. Shah CH; Pappot H; Agerbæk M; Holmsten K; Jäderling F; Yachnin J; Grybäck P; von der Maase H; Ullén A Oncologist; 2019 Jun; 24(6):745-e213. PubMed ID: 30552156 [TBL] [Abstract][Full Text] [Related]
23. Vinflunine in the treatment of advanced bladder cancer. Mamtani R; Vaughn DJ Expert Rev Anticancer Ther; 2011 Jan; 11(1):13-20. PubMed ID: 21166506 [TBL] [Abstract][Full Text] [Related]
24. Vinflunine: a fluorinated vinca alkaloid for bladder cancer therapy. Gerullis H Drugs Today (Barc); 2011 Jan; 47(1):17-25. PubMed ID: 21373647 [TBL] [Abstract][Full Text] [Related]
25. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy. Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325 [TBL] [Abstract][Full Text] [Related]
26. Real-World Vinflunine Outcomes in Bladder Cancer in a Single-Institution Study: Moving Beyond Clinical Trials. Moriceau G; Vallard A; Rivoirard R; Méry B; Espenel S; Langrand-Escure J; Ben Mrad M; Wang G; Diao P; Pacaut C; Guillot A; Collard O; Fournel P; Magné N Clin Genitourin Cancer; 2015 Dec; 13(6):588-92. PubMed ID: 26117277 [TBL] [Abstract][Full Text] [Related]
28. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Bellmunt J; Fougeray R; Rosenberg JE; von der Maase H; Schutz FA; Salhi Y; Culine S; Choueiri TK Ann Oncol; 2013 Jun; 24(6):1466-72. PubMed ID: 23419284 [TBL] [Abstract][Full Text] [Related]
30. A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer. Chan S; Campone M; Santoro A; Conte PF; Bostnavaron M; Nguyen L Cancer Chemother Pharmacol; 2014 May; 73(5):903-10. PubMed ID: 24627219 [TBL] [Abstract][Full Text] [Related]
31. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder. Ortmann CA; Mazhar D Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324 [TBL] [Abstract][Full Text] [Related]
32. Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational Study. Heers H; DE Geeter P; Goebell PJ; Matz U; DE Schultz W; Edlich B; Retz M; Hegele A Anticancer Res; 2017 Nov; 37(11):6437-6442. PubMed ID: 29061830 [TBL] [Abstract][Full Text] [Related]
33. Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid. Schutz FA; Bellmunt J; Rosenberg JE; Choueiri TK Expert Opin Drug Saf; 2011 Jul; 10(4):645-53. PubMed ID: 21524237 [TBL] [Abstract][Full Text] [Related]
34. Targeted agents in second-line bladder cancer therapy. Gerullis H; Otto T; Ecke TH Anticancer Drugs; 2012 Nov; 23(10):1003-15. PubMed ID: 22914698 [TBL] [Abstract][Full Text] [Related]
35. Phase I and pharmacokinetic study of IV vinflunine in combination with carboplatin in chemonaive patients with advanced non-small cell lung cancer. Tournoux-Facon C; Robinet G; Pinel MC; Ferre P; Tourani JM Am J Clin Oncol; 2012 Aug; 35(4):378-85. PubMed ID: 22814308 [TBL] [Abstract][Full Text] [Related]